We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
Read MoreHide Full Article
Key Takeaways
Viking Therapeutics' Q2 report is expected to spotlight updates on its VK2735 obesity pipeline.
VKTX is advancing late-stage VK2735 studies, with key data not expected before next year.
VKTX plans SC maintenance results on VK2735 in Q3 2026 and late-stage oral program initiation in Q4 2026.
We expect investors to focus on updates related to Viking Therapeutics’ (VKTX - Free Report) pipeline when it reports second-quarter 2026 earnings. In the last reported quarter, the company’s earnings missed expectations by more than 44%.
Since the company lacks a marketed drug in its portfolio, no revenues are expected to have been recorded. The Zacks Consensus Estimate for earnings is pegged at a loss of $1.21 per share.
Factors Likely to Shape VKTX’s Upcoming Results
Investor focus will likely be on pipeline updates. Viking Therapeutics’ lead candidate is VK2735, which is being developed to treat obesity.
The company is conducting two late-stage studies (VANQUISH-1 and VANQUISH-2) on the subcutaneous (SC) formulation of VK2735. While VANQUISH-1 is evaluating the drug in obese adults with at least one weight-related co-morbid condition and without type II diabetes (T2D), VANQUISH-2 is assessing its efficacy in obese or overweight adults with T2D. Data from these studies is not expected before next year.
Investors will likely be seeking updates on the ongoing maintenance dosing study on VK2735, which was initiated last year. This study is evaluating multiple regimens — monthly SC, weekly oral and daily oral dosing — to determine whether the initial weight loss achieved with weekly SC dosing can be sustained. The company had previously announced that it would report SC maintenance results in the third quarter of 2026, followed by oral maintenance results in the first half of 2027.
Investors will also likely be interested in seeking updates from VKTX on the study design for the late-stage program on the oral version of VK2735. Viking Therapeutics had previously announced plans to start the program in the fourth quarter of 2026.
VKTX’s Earnings Surprise History
The biotech firm’s performance has been dismal over the past four quarters. Its earnings missed estimates in each of the trailing four quarters, delivering a negative average surprise of 36.70%.
Year to date, shares of the company have gained more than 3% compared withthe industry’s nearly 2% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for VKTX
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or#3 (Hold) have a good chance of delivering an earnings beat. This is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Absci Corporation (ABSI - Free Report) has an Earnings ESP of +15.22% and a Zacks Rank #2 at present.
Shares of ABSI have skyrocketed about 136% year to date. The company’s earnings beat estimates in one of the trailing four quarters, while missing the mark on the other three occasions. Agenus delivered an average negative surprise of 17.58%. Absci will report second-quarter 2026 earnings on Aug. 11, after market close.
Edgewise Therapeutics (EWTX - Free Report) has an Earnings ESP of +13.28% and a Zacks Rank #2 at present.
Shares of EWTX have surged 54% year to date. The company’s earnings beat estimates in three of the trailing four quarters while missing out on one occasion, delivering an average surprise of 5.06%.
View the Zacks #1 Rank List
Image: Bigstock
Viking Therapeutics to Report Q2 Earnings: What's in Store for the Stock?
Key Takeaways
We expect investors to focus on updates related to Viking Therapeutics’ (VKTX - Free Report) pipeline when it reports second-quarter 2026 earnings. In the last reported quarter, the company’s earnings missed expectations by more than 44%.
Since the company lacks a marketed drug in its portfolio, no revenues are expected to have been recorded. The Zacks Consensus Estimate for earnings is pegged at a loss of $1.21 per share.
Factors Likely to Shape VKTX’s Upcoming Results
Investor focus will likely be on pipeline updates. Viking Therapeutics’ lead candidate is VK2735, which is being developed to treat obesity.
The company is conducting two late-stage studies (VANQUISH-1 and VANQUISH-2) on the subcutaneous (SC) formulation of VK2735. While VANQUISH-1 is evaluating the drug in obese adults with at least one weight-related co-morbid condition and without type II diabetes (T2D), VANQUISH-2 is assessing its efficacy in obese or overweight adults with T2D. Data from these studies is not expected before next year.
Investors will likely be seeking updates on the ongoing maintenance dosing study on VK2735, which was initiated last year. This study is evaluating multiple regimens — monthly SC, weekly oral and daily oral dosing — to determine whether the initial weight loss achieved with weekly SC dosing can be sustained. The company had previously announced that it would report SC maintenance results in the third quarter of 2026, followed by oral maintenance results in the first half of 2027.
Investors will also likely be interested in seeking updates from VKTX on the study design for the late-stage program on the oral version of VK2735. Viking Therapeutics had previously announced plans to start the program in the fourth quarter of 2026.
VKTX’s Earnings Surprise History
The biotech firm’s performance has been dismal over the past four quarters. Its earnings missed estimates in each of the trailing four quarters, delivering a negative average surprise of 36.70%.
Viking Therapeutics, Inc. Price and EPS Surprise
Viking Therapeutics, Inc. price-eps-surprise | Viking Therapeutics, Inc. Quote
VKTX Stock Performance
Year to date, shares of the company have gained more than 3% compared withthe industry’s nearly 2% growth.
Image Source: Zacks Investment Research
What Our Model Predicts for VKTX
Per our proven model, companies with the combination of a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or#3 (Hold) have a good chance of delivering an earnings beat. This is not the case here. You can uncover the best stocks to buy or sell before they're reported with our Earnings ESP Filter.
Viking has an Earnings ESP of 0.00% and a Zacks Rank #4 (Sell) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Stocks With Favorable Combinations
Here are some drug/biotech stocks that have the right combination of elements to beat on earnings this time around:
Absci Corporation (ABSI - Free Report) has an Earnings ESP of +15.22% and a Zacks Rank #2 at present.
Shares of ABSI have skyrocketed about 136% year to date. The company’s earnings beat estimates in one of the trailing four quarters, while missing the mark on the other three occasions. Agenus delivered an average negative surprise of 17.58%. Absci will report second-quarter 2026 earnings on Aug. 11, after market close.
Edgewise Therapeutics (EWTX - Free Report) has an Earnings ESP of +13.28% and a Zacks Rank #2 at present.
Shares of EWTX have surged 54% year to date. The company’s earnings beat estimates in three of the trailing four quarters while missing out on one occasion, delivering an average surprise of 5.06%.